Stryker delivered outstanding full-year 2025 results, surpassing $25 billion in sales with 10.3% organic growth, driven by double-digit expansion in MedSurg and Neurotechnology. Adjusted EPS increased 11.8% to $13.63, supported by a second consecutive year of at least 100 basis points of adjusted operating margin expansion, reaching 30.2% in Q4. Key performance drivers included record Mako robotic installations, strong capital demand, and strategic sales force specialization. For 2026, management guides for organic sales growth of 8% to 9.5% and adjusted EPS of $14.90 to $15.10, reflecting confidence in durable procedural volumes and new product launches despite anticipated tariff headwinds of $400 million.
| Metric | Value | Change |
|---|---|---|
| Sales (Full Year 2025) | >$25 Billion | +10.3% Organic |
| Organic Sales Growth (Q4 2025) | 11.0% | vs 10.2% in Q4 2024 |
| Adjusted EPS (Full Year 2025) | $13.63 | +11.8% |
| Adjusted Operating Margin (Q4 2025) | 30.2% | +100 bps |
| Free Cash Flow (Full Year 2025) | $5 Billion | +$820 Million |
| Mako Installed Base | >3,000 | Record Quarter |
Stryker's robotics franchise is establishing a durable competitive moat. The transition to Mako 4 resulted in a 'stunning' quarter of installations, growing the installed base to over 3,000 units globally. Utilization rates are high, with over two-thirds of U.S. knees and one-third of hips now performed on Mako. This high utilization drives recurring instrument revenue and creates switching costs for hospitals. Management believes robotics has no limit and could become the standard of care, positioning Stryker for long-term share gains.
The MedSurg division is executing a 'secret sauce' strategy of systematic specialization to drive double-digit growth. By splitting sales forces (e.g., creating dedicated breast care and infection control teams) and combining internal innovation with tuck-in acquisitions, Stryker is penetrating deeper into existing accounts. This strategy allows them to grow faster than the underlying market by addressing specific clinical niches with specialized portfolios, as evidenced by the 12.6% organic growth in MedSurg and Neurotechnology.
Stryker is demonstrating significant pricing power and operational efficiency. Despite inflationary pressures and $400 million in tariff headwinds for 2026, management expects pricing to remain 'modestly positive' and continues to guide for operating margin expansion. CFO Preston Wells noted that pricing gains are building on previous years' successes, and the company is effectively offsetting tariffs through supply chain optimization and mix improvements, signaling strong earnings power.
The company is actively leveraging its strong balance sheet and free cash flow (81% conversion) for M&A. With the promotion of Spencer Stiles to COO, CEO Kevin Lobo intends to focus more on M&A and AI integration. Management indicated a healthy pipeline for tuck-in acquisitions, specifically in adjacencies to the recent Inari (Vascular) and Care AI (Health IT) deals. This capital deployment strategy supports the 'high-growth offense' and diversifies revenue streams.
New product innovation remains a primary growth vector for 2026 and beyond. The launch of Mako RPS (handheld robot) is off to a strong start, addressing a segment of surgeons not ready for full robotic change management. Additionally, the Triathlon Gold knee implant is in limited launch with positive feedback, addressing a 5% market gap for Stryker. These launches, combined with new software applications for Mako (shoulder, spine), provide a robust product cycle.
Stryker faces a significant and growing tariff headwind, estimated at $400 million for 2026, which includes an incremental $200 million compared to 2025. While management is confident in their ability to mitigate these costs through pricing and operational efficiency, this represents a persistent drag on profitability that requires constant offset. The guidance assumes successful mitigation, leaving little room for error if cost inflation proves stickier than anticipated.
The Vascular division continues to experience competitive pressures, specifically in the ischemic business, which grew only 4.3% organically in the U.S. Management acknowledged that this sector has been 'tough' for a couple of years. While the hemorrhagic business and the new Inari acquisition are performing well, the struggles in ischemic highlight a competitive vulnerability in a key market that could limit overall segment growth.
The capital environment in Europe showed signs of slowing during Q4, described as a 'slower capital environment' by management. While this was offset by strength in other international markets like Australia and South Korea, a prolonged slowdown in European capital spending could dampen the growth trajectory of Stryker's capital-heavy businesses, such as Mako and surgical equipment.
Regulatory hurdles in Europe, specifically the EU MDR (Medical Device Regulation), are delaying product launches. CEO Kevin Lobo noted that approvals for key products like Insignia and Pangaea have been 'extremely frustrating' and slower than in the U.S. While potential simplification of MDR is on the horizon, these delays currently restrict revenue realization in international markets compared to the U.S.
Overall: Management exhibited a highly confident and enthusiastic demeanor throughout the call, frequently using strong superlatives such as 'outstanding,' 'stunning,' and 'home run' to describe performance. There was no defensiveness regarding competitive pressures or tariff headwinds; instead, executives emphasized their operational 'muscle' and ability to absorb costs while expanding margins. The tone shifted from celebratory in prepared remarks to detailed and assured during the Q&A, reinforcing their strategic outlook.
Confidence: HIGH - Management provided specific guidance ranges, detailed product roadmaps, and articulated clear strategies for offsetting headwinds. The language was decisive regarding market share gains and the success of new product launches like Mako 4.
8.0% to 9.5%
$14.90 to $15.10
15.0% to 16.0%
Approximately $400 million (includes $200M incremental)
70% to 80% of adjusted net earnings
Hedging & Uncertainty: Management displayed minimal hedging regarding their core business performance, using definitive language like 'outstanding,' 'stunning,' and 'home run.' However, slight hedging appeared when discussing the upper limits of 2026 growth potential and macro factors. For example, CEO Kevin Lobo stated, '10% is certainly possible. But it does depend on a lot of things that are in the macro environment procedure growth.' This indicates confidence in internal execution but a cautious acknowledgment of external variables. The use of 'expect' and 'anticipate' regarding guidance was firm, supported by specific data points like the 'elevated' order book.
Mako-four is been an absolute home run. - Kevin Lobo, Chair and CEO
Our margin muscle is really good. This is not something I could have said, you know, seven, eight years ago. - Kevin Lobo, Chair and CEO
We're on offense right now looking at deals. - Kevin Lobo, Chair and CEO
I don't see a limit [to robotics]. - Kevin Lobo, Chair and CEO
We expect 2026 organic net sales growth to be in the range of 8% to 9.5%. - Preston Wells, CFO
We have really a strong balance sheet right now. - Kevin Lobo, Chair and CEO
The feedback has been incredible. From the surgeons using it, like, this is easy to use. - Kevin Lobo, Chair and CEO (on Mako RPS)
Analyst Sentiment: Analysts were highly positive and congratulatory, frequently commending management on the 'strong end to the year' and 'terrific' performance. Questions focused heavily on the sustainability of the growth rate, specifically regarding the durability of Mako demand and the pricing environment.
Management Responses: Management responses were detailed, open, and confident. Executives provided granular data on utilization rates and specific product cycles (e.g., Triathlon Gold, Mako RPS) to support their thesis. They deflected concerns about tariffs and vascular competition by pointing to offsetting strengths and operational improvements.
Mako Robotics: Analysts sought confirmation on the durability of the 'stunning' installation rates and the potential for incremental reimbursement. Management confirmed strong feedback and high utilization.
Pricing Strategy: Questions centered on the sustainability of price increases in 2026. Management affirmed expectations for pricing similar to 2025, driven by 'muscle' developed in contracting.
Vascular Segment: Analysts asked about the underperformance in ischemic vascular. Management acknowledged the competitive pressure but highlighted strength in hemorrhagic and the new Inari business.
M&A: Interest was high regarding the 'healthy' deal pipeline and specific focus areas (vascular, HIT). Management confirmed an active stance but remained vague on specific targets.
Margins: Analysts asked about the ability to expand margins amidst tariff headwinds. Management expressed high confidence in their 'margin muscle' and operational excellence.
Stryker is executing at a high level across all business units, delivering double-digit organic growth and significant margin expansion. The company's 'high-growth offense'—characterized by robotic leadership (Mako), specialized sales forces, and disciplined M&A—is creating a durable competitive advantage and widening the gap with peers. The 2026 guidance for 8-9.5% organic growth and ~10% EPS growth, even in the face of $400M in tariffs, underscores the strength of the business model and operational execution. The stock offers a compelling combination of growth, profitability, and strategic momentum, warranting a positive investment stance.
Management reported that 'Hospital CapEx budgets remain healthy, and our capital order book continues to be elevated as we enter 2026.' This suggests that the hospital sector is financially stable and willing to invest in new equipment, boding well for Stryker's capital-heavy businesses.
Executives noted that 'Procedural volumes remained healthy in the fourth quarter' and are expected to remain strong in 2026. This is driven by 'favorable demographics' and the adoption of robotic-assisted surgery, indicating a robust demand environment for medical procedures.
CEO Kevin Lobo expressed frustration with the EU MDR, stating it has been 'extremely frustrating' and is 'stunting innovation.' While potential simplification is welcomed, the current environment is delaying product launches and revenue realization in Europe compared to the U.S.
Management views the shift of procedures to ASCs as a net positive due to Stryker's 'broadest offering by far in the industry.' CMS moves to delete the inpatient-only list are seen as beneficial, particularly for the sports medicine business.